As the KeepSight program hit 100,000 enrolments, a new University of Sydney study has found only half of diabetics are getting the recommended eye checks, putting them at risk of significant vision loss and blindness.
Read More
KeepSight registrations hit 80,000
Registrations with eye check reminder program KeepSight have surpassed 80,000, with enrolment rates now on the rise after dropping during the initial peak of the COVID-19 outbreak.
Read More
Read More
Novartis AMD drug Beovu secures European approval
European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new anti-VEGF therapy.
Read More
Read More
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors.
Read More
Read More
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea.
Read More
Read More